ClinicalTrials.gg
CompletedNCT00811941SENSEUpdated Aug 7, 2013Results posted

Safety and Efficacy of Nalmefene in Patients With Alcohol Dependence

A Phase 3 interventional study of Placebo and Nalmefene in Alcohol Dependence, sponsored by H. Lundbeck A/S. Completed at 60 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-08-07.

Sponsored by H. Lundbeck A/S · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
665
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies testing nalmefene in Alcoholism — none open to participants now, none under way, none of them phase 3. nalmefene · Alcoholism.

Enrollment
3rd of 12
665 · median 212
Started
2009
with 1 other
Phase 3
6 of 12
none open now
Registered
1st of 12
by date
Lead sponsor
5 of 12
H. Lundbeck A/S

Among the 12 studies testing nalmefene in Alcoholism, this one is the 3rd largest by enrollment, is one of 2 that started in 2009, is one of 6 in phase 3, and was the 1st registered.

Alcoholism

1,676 studies on the registry are indexed under Alcoholism; 331 are open to participants now.

Browse Alcoholism studies →

Open to participants now

None of the 12 studies testing nalmefene in Alcoholism is open now. The open studies under Alcoholism, anywhere →

About nalmefene

nalmefene: first FDA approval 1995 (REVEX), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 237 Alcoholism studies recruiting now, 84 (35%) set no upper age limit and 131 (55%) stop at 75 or younger; 9 take children under 18; 64 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 12 studies testing nalmefene in Alcoholism as a file.
02

Study summary

The purpose of the study is long-term safety, tolerability and efficacy of nalmefene in patients with alcohol dependence.

Read the detailed description

Alcohol dependence is a maladaptive pattern of alcohol use, leading to clinically significant impairment or distress, as manifested by at least three of a number of criteria such as tolerance, withdrawal symptoms, frequent use of alcohol in larger amounts or over longer periods than was intended, and others. Excessive intake of alcohol reduces the life span by a decade, and alcohol drinking is strongly related to mortality from liver cirrhosis, chronic pancreatitis, certain cancers, hypertension, accidents and violence. This study is planned to evaluate the long-term safety and tolerability as well as to evaluate the efficacy of as needed use of 18.06 mg nalmefene in patients with alcohol dependence.

03

Conditions studied

  • Alcohol Dependence

Keywords

  • Pharmacologic Actions
  • Alcohol-Related Disorders
  • Alcoholism
  • Mental Disorders
  • Central Nervous System Agents
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

In- and outpatients who:

  • had a primary diagnosis of alcohol dependence according to - text revision (DSM-IV-TR) criteria
  • had had ≥6 Heavy Drinking Days (HDDs) in the 4 weeks preceding the Screening Visit

Exclusion criteria

Exclusion Criteria:

The patient:

  • had a severe psychiatric disorder or an antisocial personality disorder
  • had risk of suicide evaluated by the suicidality module of the Mini-International Neuropsychiatric Interview (MINI)
  • had a history of delirium tremens or alcohol withdrawal seizures
  • reported current or recent (within 3 months preceding screening) treatment with disulfiram, acamprosate, topiramate, naltrexone or carbimide, or with any opioid antagonists
  • was pregnant or breast-feeding

Other protocol-defined inclusion and exclusion criteria may apply.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
665 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Drug: Placebo

  • Experimental
    Nalmefene

    Drug: Nalmefene

Interventions

  • DrugPlacebo

    as-needed use, tablets, orally, 52 weeks

  • 18.06 mg as-needed use, tablets, orally, 52 weeks. 18.06 mg nalmefene equals 20 mg nalmefene hydrochloride.

    Also known as: Selincro™

06

What researchers measure

Primary outcomes

  1. Number of Patients With Adverse Events (AEs)

    Overview of AEs

    Time frame: Serious Adverse Events: 52 weeks and a safety follow-up (visit/telephone call) scheduled for 4 weeks after completion of the study or after withdrawal from the study. Other Adverse Events: 52 weeks.

  2. Percentage of Patients Who Withdrew Due to Intolerance to Treatment

    Time frame: Baseline to Week 52

  3. Change From Baseline in the Monthly Number of Heavy Drinking Days (HDDs)

    Number of HDDs over a month (28 days), where one HDD was defined as a day with alcohol consumption ≥60 grams (g) for men and ≥40 g for women.

    Time frame: Baseline and Month 6

  4. Change From Baseline in the Monthly Total Alcohol Consumption (TAC)

    TAC was defined as mean daily alcohol consumption in g/day over a month (28 days).

    Time frame: Baseline and Month 6

Secondary outcomes

  1. Drinking Risk Level (RSDRL) Response

    RSDRL response was defined as a downward shift from baseline in Drinking Risk Level (DRL); for patients at very high risk at Baseline: a shift to medium risk or below, and for patients at high or medium risk at Baseline: a shift to low risk or below.

    Time frame: Month 6

  2. Change From Baseline in Clinical Status Using CGI-S

    The Clinical Global Impression - Severity of Illness (CGI-S) provides the clinician's impression of the patient's current state of mental illness. The clinician uses his or her clinical experience of this patient population to rate the severity of the patient's current mental illness on a 7-point scale ranging from 1 (Normal - not at all ill) to 7 (among the most extremely ill patients).

    Time frame: Baseline and Week 24

  3. Change in Clinical Status Using the CGI-I

    The Clinical Global Impression - Global Improvement (CGI-I) provides the clinician's impression of the patient's improvement (or worsening). The clinician assesses the patient's condition relative to a baseline on a 7- point scale ranging from 1 (very much improved) to 7 (very much worse).

    Time frame: Week 24

  4. Liver Function Test Gamma-glutamyl Transferase (GGT)

    GGT values

    Time frame: Week 24

  5. Liver Function Test Alanine Aminotransferase (ALAT)

    ALAT values

    Time frame: Week 24

  6. Change From Baseline in the Monthly Number of Heavy Drinking Days (HDDs)

    Number of HDDs over a month (28 days), where one HDD was defined as a day with alcohol consumption ≥60 g for men and ≥40 g for women.

    Time frame: Baseline and Month 13

  7. Change From Baseline in the Monthly Total Alcohol Consumption (TAC)

    TAC was defined as mean daily alcohol consumption in g/day over a month (28 days).

    Time frame: Baseline and Month 13

  8. Drinking Risk Level (RSDRL) Response

    RSDRL response was defined as a downward shift from baseline in Drinking Risk Level (DRL); for patients at very high risk at Baseline: a shift to medium risk or below, and for patients at high or medium risk at Baseline: a shift to low risk or below.

    Time frame: Month 13

  9. Change From Baseline in Clinical Status Using CGI-S

    The Clinical Global Impression - Severity of Illness (CGI-S) provides the clinician's impression of the patient's current state of mental illness. The clinician uses his or her clinical experience of this patient population to rate the severity of the patient's current mental illness on a 7-point scale ranging from 1 (Normal - not at all ill) to 7 (among the most extremely ill patients).

    Time frame: Baseline and Week 52

  10. Change in Clinical Status Using the CGI-I

    The Clinical Global Impression - Global Improvement (CGI-I) provides the clinician's impression of the patient's improvement (or worsening). The clinician assesses the patient's condition relative to a baseline on a 7- point scale ranging from 1 (very much improved) to 7 (very much worse).

    Time frame: Week 52

  11. Liver Function Test Gamma-glutamyl Transferase (GGT)

    GGT values

    Time frame: Week 52

  12. Liver Function Test Alanine Aminotransferase (ALAT)

    ALAT values

    Time frame: Week 52

07

Results

Posted Aug 7, 2013

Participant flow

All Randomised Patients
Participant flow — All Randomised Patients
MilestonePlaceboNalmefene 18.06 mg
Started166509
Completed164501
Not completed28
Withdrew: Did not receive placebo/nalmefene28
All Treated Patients
Participant flow — All Treated Patients
MilestonePlaceboNalmefene 18.06 mg
Started164501
Completed112310
Not completed52191
Withdrew: Adverse event243
Withdrew: Lack of efficacy23
Withdrew: Non-compliance18
Withdrew: Protocol violation517
Withdrew: Withdrawal by subject3594
Withdrew: Lost to follow-up312
Withdrew: Other reason414

Outcome measures

PrimaryNumber of Patients With Adverse Events (AEs)

Overview of AEs

Time frame:
Serious Adverse Events: 52 weeks and a safety follow-up (visit/telephone call) scheduled for 4 weeks after completion of the study or after withdrawal from the study. Other Adverse Events: 52 weeks.
Reported as:
Number · participants
Number of Patients With Adverse Events (AEs)
participantsPlaceboNalmefene 18.06 mg
Patients with AEs103377
Patients with Serious AEs (SAEs)835
Patients with AEs Leading to Withdrawal557
PrimaryPercentage of Patients Who Withdrew Due to Intolerance to Treatment
Time frame:
Baseline to Week 52
Reported as:
Number · percentage of participants
Percentage of Patients Who Withdrew Due to Intolerance to Treatment
percentage of participantsPlaceboNalmefene 18.06 mg
Percentage of Patients Who Withdrew Due to Intolerance to Treatment1.28.6
PrimaryChange From Baseline in the Monthly Number of Heavy Drinking Days (HDDs)

Number of HDDs over a month (28 days), where one HDD was defined as a day with alcohol consumption ≥60 grams (g) for men and ≥40 g for women.

Time frame:
Baseline and Month 6
Reported as:
Mean · days
Change From Baseline in the Monthly Number of Heavy Drinking Days (HDDs)
daysPlaceboNalmefene 18.06 mg
Change From Baseline in the Monthly Number of Heavy Drinking Days (HDDs)-8.92 ± 0.56-9.80 ± 0.35
Statistical analysis
  • Placebo vs Nalmefene 18.06 mg · Adjusted change from Baseline to Month 6 · p = 0.160 · Mean difference (final values): -0.88 · 95% CI -2.10 to 0.35The Number of Participants Analyzed is participants with efficacy measurement available at this endpoint, that is, 110 participants in the placebo group and 320 participants in the nalmefene group.
PrimaryChange From Baseline in the Monthly Total Alcohol Consumption (TAC)

TAC was defined as mean daily alcohol consumption in g/day over a month (28 days).

Time frame:
Baseline and Month 6
Reported as:
Mean · g
Change From Baseline in the Monthly Total Alcohol Consumption (TAC)
gPlaceboNalmefene 18.06 mg
Change From Baseline in the Monthly Total Alcohol Consumption (TAC)-45.58 ± 2.61-49.05 ± 1.64
Statistical analysis
  • Placebo vs Nalmefene 18.06 mg · Adjusted change from Baseline to Month 6 · p = 0.232 · Mean difference (final values): -3.47 · 95% CI -9.17 to 2.23The Number of Participants Analyzed is participants with efficacy measurement available at this endpoint, that is, 110 participants in the placebo group and 320 participants in the nalmefene group.
SecondaryDrinking Risk Level (RSDRL) Response

RSDRL response was defined as a downward shift from baseline in Drinking Risk Level (DRL); for patients at very high risk at Baseline: a shift to medium risk or below, and for patients at high or medium risk at Baseline: a shift to low risk or below.

Time frame:
Month 6
Reported as:
Number · percentage of participants
Drinking Risk Level (RSDRL) Response
percentage of participantsPlaceboNalmefene 18.06 mg
Drinking Risk Level (RSDRL) Response63.562.2
Statistical analysis
  • Placebo vs Nalmefene 18.06 mg · Adjusted Odds Ratio (OR) response · p = 0.689 · Odds ratio (or): 0.92 · 95% CI 0.59 to 1.41
SecondaryChange From Baseline in Clinical Status Using CGI-S

The Clinical Global Impression - Severity of Illness (CGI-S) provides the clinician's impression of the patient's current state of mental illness. The clinician uses his or her clinical experience of this patient population to rate the severity of the patient's current mental illness on a 7-point scale ranging from 1 (Normal - not at all ill) to 7 (among the most extremely ill patients).

Time frame:
Baseline and Week 24
Reported as:
Mean · units on a scale
Change From Baseline in Clinical Status Using CGI-S
units on a scalePlaceboNalmefene 18.06 mg
Change From Baseline in Clinical Status Using CGI-S-0.75 ± 0.08-0.94 ± 0.05
Statistical analysis
  • Placebo vs Nalmefene 18.06 mg · Adjusted change from Baseline to Week 24 · p = 0.046 · Mean difference (final values): -0.18 · 95% CI -0.37 to -0.00The Number of Participants Analyzed is participants with efficacy measurement available at this endpoint, that is, 104 participants in the placebo group and 306 participants in the nalmefene group.
SecondaryChange in Clinical Status Using the CGI-I

The Clinical Global Impression - Global Improvement (CGI-I) provides the clinician's impression of the patient's improvement (or worsening). The clinician assesses the patient's condition relative to a baseline on a 7- point scale ranging from 1 (very much improved) to 7 (very much worse).

Time frame:
Week 24
Reported as:
Mean · units on a scale
Change in Clinical Status Using the CGI-I
units on a scalePlaceboNalmefene 18.06 mg
Change in Clinical Status Using the CGI-I2.68 ± 0.102.54 ± 0.06
Statistical analysis
  • Placebo vs Nalmefene 18.06 mg · Adjusted change from Baseline to Week 24 · p = 0.217 · Mean difference (final values): -0.14 · 95% CI -0.36 to 0.08The Number of Participants Analyzed is participants with efficacy measurement available at this endpoint, that is, 104 participants in the placebo group and 306 participants in the nalmefene group.
SecondaryLiver Function Test Gamma-glutamyl Transferase (GGT)

GGT values

Time frame:
Week 24
Reported as:
Geometric mean · IU/L
Liver Function Test Gamma-glutamyl Transferase (GGT)
IU/LPlaceboNalmefene 18.06 mg
Liver Function Test Gamma-glutamyl Transferase (GGT)34.5 ± 63.532.2 ± 71.1
Statistical analysis
  • Placebo vs Nalmefene 18.06 mg · Adjusted values · p = 0.273 · Ratio to placebo: 0.93 · 95% CI 0.83 to 1.05The Number of Participants Analyzed is participants with efficacy measurement available at this endpoint, that is, 108 participants in the placebo group and 319 participants in the nalmefene group.
SecondaryLiver Function Test Alanine Aminotransferase (ALAT)

ALAT values

Time frame:
Week 24
Reported as:
Geometric mean · IU/L
Liver Function Test Alanine Aminotransferase (ALAT)
IU/LPlaceboNalmefene 18.06 mg
Liver Function Test Alanine Aminotransferase (ALAT)25.8 ± 52.425.6 ± 56.7
Statistical analysis
  • Placebo vs Nalmefene 18.06 mg · Adjusted values · p = 0.916 · Ratio to placebo: 0.99 · 95% CI 0.90 to 1.10The Number of Participants Analyzed is participants with efficacy measurement available at this endpoint, that is, 108 participants in the placebo group and 318 participants in the nalmefene group.
SecondaryChange From Baseline in the Monthly Number of Heavy Drinking Days (HDDs)

Number of HDDs over a month (28 days), where one HDD was defined as a day with alcohol consumption ≥60 g for men and ≥40 g for women.

Time frame:
Baseline and Month 13
Reported as:
Mean · days
Change From Baseline in the Monthly Number of Heavy Drinking Days (HDDs)
daysPlaceboNalmefene 18.06 mg
Change From Baseline in the Monthly Number of Heavy Drinking Days (HDDs)-8.96 ± 0.58-10.53 ± 0.37
Statistical analysis
  • Placebo vs Nalmefene 18.06 mg · Adjusted change from Baseline - Month 13 · p = 0.017 · Mean difference (final values): -1.57 · 95% CI -2.85 to -0.29The Number of Participants Analyzed is participants with efficacy measurement available at this endpoint, that is, 97 participants in the placebo group and 258 participants in the nalmefene group.
SecondaryChange From Baseline in the Monthly Total Alcohol Consumption (TAC)

TAC was defined as mean daily alcohol consumption in g/day over a month (28 days).

Time frame:
Baseline and Month 13
Reported as:
Mean · g
Change From Baseline in the Monthly Total Alcohol Consumption (TAC)
gPlaceboNalmefene 18.06 mg
Change From Baseline in the Monthly Total Alcohol Consumption (TAC)-46.33 ± 2.73-52.80 ± 1.76
Statistical analysis
  • Placebo vs Nalmefene 18.06 mg · Adjusted change from Baseline - Month 13 · p = 0.036 · Mean difference (final values): -6.47 · 95% CI -12.53 to -0.42The Number of Participants Analyzed is participants with efficacy measurement available at this endpoint, that is, 97 participants in the placebo group and 258 participants in the nalmefene group.
SecondaryDrinking Risk Level (RSDRL) Response

RSDRL response was defined as a downward shift from baseline in Drinking Risk Level (DRL); for patients at very high risk at Baseline: a shift to medium risk or below, and for patients at high or medium risk at Baseline: a shift to low risk or below.

Time frame:
Month 13
Reported as:
Number · percentage of participants
Drinking Risk Level (RSDRL) Response
percentage of participantsPlaceboNalmefene 18.06 mg
Drinking Risk Level (RSDRL) Response54.054.5
Statistical analysis
  • Placebo vs Nalmefene 18.06 mg · Adjusted Odds Ratio (OR) response · p = 0.976 · Odds ratio (or): 1.01 · 95% CI 0.67 to 1.52
SecondaryChange From Baseline in Clinical Status Using CGI-S

The Clinical Global Impression - Severity of Illness (CGI-S) provides the clinician's impression of the patient's current state of mental illness. The clinician uses his or her clinical experience of this patient population to rate the severity of the patient's current mental illness on a 7-point scale ranging from 1 (Normal - not at all ill) to 7 (among the most extremely ill patients).

Time frame:
Baseline and Week 52
Reported as:
Mean · units on a scale
Change From Baseline in Clinical Status Using CGI-S
units on a scalePlaceboNalmefene 18.06 mg
Change From Baseline in Clinical Status Using CGI-S-1.08 ± 0.10-1.30 ± 0.06
Statistical analysis
  • Placebo vs Nalmefene 18.06 mg · Adjusted change from Baseline to Week 52 · p = 0.056 · Mean difference (final values): -0.22 · 95% CI -0.44 to 0.01The Number of Participants Analyzed is participants with efficacy measurement available at this endpoint, that is, 95 participants in the placebo group and 258 participants in the nalmefene group.
SecondaryChange in Clinical Status Using the CGI-I

The Clinical Global Impression - Global Improvement (CGI-I) provides the clinician's impression of the patient's improvement (or worsening). The clinician assesses the patient's condition relative to a baseline on a 7- point scale ranging from 1 (very much improved) to 7 (very much worse).

Time frame:
Week 52
Reported as:
Mean · units on a scale
Change in Clinical Status Using the CGI-I
units on a scalePlaceboNalmefene 18.06 mg
Change in Clinical Status Using the CGI-I2.52 ± 0.102.26 ± 0.06
Statistical analysis
  • Placebo vs Nalmefene 18.06 mg · Adjusted change from Baseline to Week 52 · p = 0.029 · Mean difference (final values): -0.26 · 95% CI -0.50 to -0.03The Number of Participants Analyzed is participants with efficacy measurement available at this endpoint, that is, 95 participants in the placebo group and 258 participants in the nalmefene group.
SecondaryLiver Function Test Gamma-glutamyl Transferase (GGT)

GGT values

Time frame:
Week 52
Reported as:
Geometric mean · IU/L
Liver Function Test Gamma-glutamyl Transferase (GGT)
IU/LPlaceboNalmefene 18.06 mg
Liver Function Test Gamma-glutamyl Transferase (GGT)41.3 ± 76.232.0 ± 80.6
Statistical analysis
  • Placebo vs Nalmefene 18.06 mg · Adjusted values · p = 0.001 · Ratio to placebo: 0.78 · 95% CI 0.67 to 0.90The Number of Participants Analyzed is participants with efficacy measurement available at this endpoint, that is, 98 participants in the placebo group and 259 participants in the nalmefene group.
SecondaryLiver Function Test Alanine Aminotransferase (ALAT)

ALAT values

Time frame:
Week 52
Reported as:
Geometric mean · IU/L
Liver Function Test Alanine Aminotransferase (ALAT)
IU/LPlaceboNalmefene 18.06 mg
Liver Function Test Alanine Aminotransferase (ALAT)27.8 ± 55.624.6 ± 58.5
Statistical analysis
  • Placebo vs Nalmefene 18.06 mg · Adjusted values · p = 0.037 · Ratio to placebo: 0.88 · 95% CI 0.79 to 0.99The Number of Participants Analyzed is participants with efficacy measurement available at this endpoint, that is, 97 participants in the placebo group and 259 participants in the nalmefene group.

Adverse events

Collected over Serious Adverse Events: 52 weeks and a safety follow-up (visit/telephone call) scheduled for 4 weeks after completion of the study or after withdrawal from the study. Other Adverse Events: 52 weeks.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—8/164 (4.9%)57/164 (34.8%)
Nalmefene 18.06 mg—35/501 (7%)273/501 (54.5%)
Most frequent serious events
Showing 10 of 46
Most frequent serious events
EventPlaceboNalmefene 18.06 mg
Alcohol withdrawal syndromePsychiatric disorders1/1649/501
Crohn's diseaseGastrointestinal disorders1/1640/501
Diverticulum intestinalGastrointestinal disorders1/1640/501
Liver disorderHepatobiliary disorders1/1640/501
Abscess limbInfections and infestations1/1640/501
PneumoniaInfections and infestations1/1641/501
PyelonephritisInfections and infestations1/1640/501
PyothoraxInfections and infestations1/1640/501
Fibula fractureInjury, poisoning and procedural complications1/1640/501
Rib fractureInjury, poisoning and procedural complications1/1640/501
Most frequent other events
Most frequent other events
EventPlaceboNalmefene 18.06 mg
NauseaGastrointestinal disorders9/164112/501
DizzinessNervous system disorders6/16473/501
InsomniaPsychiatric disorders11/16473/501
HeadacheNervous system disorders13/16461/501
NasopharyngitisInfections and infestations19/16454/501
VomitingGastrointestinal disorders2/16457/501
SomnolenceNervous system disorders8/16442/501
FallInjury, poisoning and procedural complications11/1645/501
Accidental overdoseInjury, poisoning and procedural complications9/1649/501
FatigueGeneral disorders3/16427/501

Baseline characteristics

Age Continuous
Age Continuous(years)PlaceboNalmefene 18.06 mgTotal
Mean44.3 ± 12.044.3 ± 11.244.3 ± 11.4
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboNalmefene 18.06 mgTotal
Female39116155
Male127393520
Previously Treated for Alcohol Dependence
Previously Treated for Alcohol Dependence(participants)PlaceboNalmefene 18.06 mgTotal
NO105338443
YES61171232
Previously Treated for Alcohol Withdrawal Symptoms
Previously Treated for Alcohol Withdrawal Symptoms(participants)PlaceboNalmefene 18.06 mgTotal
NO118372490
YES48137185
Total Monthly Heavy Drinking Days (HDD)
Total Monthly Heavy Drinking Days (HDD)(days)PlaceboNalmefene 18.06 mgTotal
Mean13.69 ± 6.0314.08 ± 6.2213.98 ± 6.17
Total Alcohol Consumption (TAC) g Alcohol/Day
Total Alcohol Consumption (TAC) g Alcohol/Day(g)PlaceboNalmefene 18.06 mgTotal
Mean68.00 ± 40.6268.64 ± 39.9868.49 ± 40.11
Drinking Risk Level (DRL)
Drinking Risk Level (DRL)(participants)PlaceboNalmefene 18.06 mgTotal
UNKNOWN011
LOW2679105
MEDIUM49167216
HIGH59148207
VERY HIGH32114146
Clinical Global Impression - Severity of Illness (CGI-S)
Clinical Global Impression - Severity of Illness (CGI-S)(units on a scale)PlaceboNalmefene 18.06 mgTotal
Mean3.88 ± 1.033.95 ± 1.123.94 ± 1.09

2 further baseline measures are reported on the registry.

08

Study locations

60 sites
  • CZ007
    Litomerice, 412 01, Czech Republic
  • CZ006
    Lnare, 38742, Czech Republic
  • CZ005
    Prague, 100 00, Czech Republic
  • CZ004
    Praha 6, 160 00, Czech Republic
  • CZ001
    Usti nad Labem, 400 13, Czech Republic
  • EE002
    Parnu, 80012, Estonia
  • EE004
    Tallinn, 10613, Estonia
  • EE005
    Tallinn, 10613, Estonia
  • EE003
    Vorumaa, 65526, Estonia
  • EE001
    Voru, 65608, Estonia
  • HU004
    Budapest, 1135, Hungary
  • HU002
    Budapest, 1163, Hungary
  • LV003
    Daugavpils, 5403, Latvia
  • LV002
    Jelgava, 3008, Latvia
  • LV001
    Riga, 1013, Latvia
  • LV004
    Sigulda, 2150, Latvia
  • LT002
    Kaunas, 44184, Lithuania
  • LT003
    Kaunas, 50185, Lithuania
  • PL015
    Belchatow, 97-400, Poland
  • PL008
    Bydgoszcz, 85-096, Poland
  • PL006
    Gdansk, 80-211, Poland
  • PL011
    Krakow, 31-826, Poland
  • PL002
    Leszno, 64-100, Poland
  • PL010
    Lodz, 91-229, Poland
  • PL014
    Lodz, 91-229, Poland
  • PL004
    Lublin, 20-015, Poland
  • PL005
    Lublin, 20-109, Poland
  • PL013
    Piekary Slaskie, 41-940, Poland
  • PL003
    Skorzewo, 60-185, Poland
  • PL007
    Starogard Gdanski, 83-200, Poland
  • PL012
    Swicie n/Wisla, 86-100, Poland
  • PL009
    Szczecin, 71-460, Poland
  • PL001
    Torun, 87-100, Poland
  • RU002
    Leningrad, 18861, Russian Federation
  • RU013
    Rostov on Don, 344010, Russian Federation
  • RU005
    St. Petersburg, 192019, Russian Federation
  • RU006
    St. Petersburg, 192019, Russian Federation
  • RU001
    St. Petersburg, 193015, Russian Federation
  • RU012
    St. Petersburg, 194022, Russian Federation
  • RU003
    St. Petersburg, 197198, Russian Federation
  • RU004
    Voronezh, 394000, Russian Federation
  • SK001
    Banska Bysterica, 974 01, Slovakia
  • SK002
    Krupina, 963 01, Slovakia
  • SK004
    Nitra, 949 01, Slovakia
  • SK005
    Rimavska Sobota, 97912, Slovakia
  • UA001
    Chernihiv, 14000, Ukraine
  • UA008
    Dnipropetrovsk, 49616, Ukraine
  • UA003
    Donetsk, 83037, Ukraine
  • UA004
    Glevakha, 8630, Ukraine
  • UA007
    Kharkiv, 61068, Ukraine
  • UA009
    Kherson, 73488, Ukraine
  • UA002
    Kyiv, 4080, Ukraine
  • UA005
    Odessa, 65006, Ukraine
  • UA006
    Simferopol, 95006, Ukraine
  • UA010
    Ternopil, 46020, Ukraine
  • GB007
    Birmingham, B15 2SQ, United Kingdom
  • GB006
    Glasgow, United Kingdom
  • GB009
    London, United Kingdom
  • GB008
    Manchester, M15 6SX, United Kingdom
  • GB005
    Reading, RG2 0TG, United Kingdom
09

References and documents

Publications

  • Laramee P, Brodtkorb TH, Rahhali N, Knight C, Barbosa C, Francois C, Toumi M, Daeppen JB, Rehm J. The cost-effectiveness and public health benefit of nalmefene added to psychosocial support for the reduction of alcohol consumption in alcohol-dependent patients with high/very high drinking risk levels: a Markov model. BMJ Open. 2014 Sep 16;4(9):e005376. doi: 10.1136/bmjopen-2014-005376. PubMed 25227627 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2009, a primary completion of Nov 2010 and a completion of Nov 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2013, 2 years 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 18, 2008
First posted
Dec 19, 2008
Start
Mar 2009
Primary completionActual
Nov 2010
CompletionActual
Nov 2010
Results first posted
Aug 7, 2013
Last update
Aug 7, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 7, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00811941
Lead sponsor
H. Lundbeck A/S
Responsible party
Sponsor
First posted
Dec 19, 2008
Start date
Mar 2009
Primary completion
Nov 2010
Completion
Nov 2010
Results posted
Aug 7, 2013
Last update
Aug 7, 2013

Study contacts

Email contact via H. Lundbeck A/S
study director · LundbeckClinicalTrials@lundbeck.com

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nalmefene

Start the discussion